| Name | Title | Contact Details |
|---|
Through our smart digital marketing & online acquisition technology, worldwide customer support operations, and innovative customer experience platform, ibex helps Fortune 500 brands acquire, engage, and retain valuable customers. Headquartered in Washington, D.C., ibex has delivery locations across 25 sites in seven countries, and maintains a network of 15,000 employees. With our CLX platform, we help brands process 180 million customer interactions yearly, add over $2B in lifetime customer revenue each year, and manage and optimize innovative customer experience programs. Our clients are Fortune 500 and other high-profile companies in a variety of industries including communications and media, technology, automotive, retail, insurance, and financial services. We have been delivering superior technology and services for over 15 years and offer an integrated suite of service including: • Digital Marketing & Customer Acquisition • Worldwide Customer Support • Business & Consumer inbound and outbound telesales & technical support • Customer Experience Management • Interactive Voice Response (IVR) • Chat & E-mail sales & support • Back office services ibex has 25 service delivery locations in the following seven (7) countries: 1. USA 2. UK 3. Philippines 4. Senegal 5. Pakistan 6. Nicaragua 7. Jamaica
Citation Management is a Milwaukee, WI-based company in the Business Services sector.
Kirkes Electric is a Turlock, CA-based company in the Business Services sector.
ClearStaff is a Woodridge, IL-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.